Table 1.
Demographic and clinical characteristics of patients (n=110)
| Characteristic | Patients |
|---|---|
| Sex (%) | |
| Male | 33.6 |
| Female | 66.4 |
| Age at start of treatment with Rebismart® (years) | |
| Median | 38.8 |
| Standard deviation | 9.3 |
| Evolutionary form of disease (%) | |
| RRMS | 93.6 |
| SPMS | 6.4 |
| EDSS at start of treatment (%) | |
| 0–2 | 79.1 |
| 2.5–4 | 19.1 |
| >4.5 | 1.8 |
| Years since diagnosis | |
| Median | 10 |
| Interquartile range | 7.0–14.3 |
| Treatment prior to Rebismart (%) | |
| Interferon β-1a (Rebif®) | 59.1 |
| Interferon β-1b (Betaferon®) | 6.4 |
| Interferon β-1a (Avonex®) | 8.2 |
| Glatiramer acetate (Copaxone®) | 4.5 |
| Azathioprine (Imurel®) | 0.9 |
| Fingolimod (clinical trial) | 1.8 |
Abbreviations: RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; EDSS, Expanded Disability Status Scale.